Option chain shows key data for BioRestorative Therapies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BioRestorative Therapies.

BioRestorative Therapies (NASDAQ:BRTX) Stock, Option Chain

BioRestorative Therapies

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Screenshot 2024-11-20 at 6.30.30 PM

Biotech

General

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-11-15 at 7.50.34 PM

BCLI

LGVN

MESO

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

Back.Lowerback.pain

News

Health Care

BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients.

BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies Inc

<h3>Gainers</h3>
<ul>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock rose 168.9% to $9.52 during Thursday's pre-market session. The company's market cap stands at $196.3 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock moved upwards by 67.86% to $6.53. The market value of their outstanding shares is at $3.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 30.95% to $3.3. The market value of their outstanding shares is at $2.7 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock increased by 16.43% to $14.81. The company's market cap stands at $673.4 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock increased by 15.0% to $6.9. The company's market cap stands at $143.5 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock increased by 13.38% to $11.0. The market value of their outstanding shares is at $90.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock fell 32.4% to $0.5 during Thursday's pre-market session. The company's market cap stands at $96.8 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock declined by 24.26% to $4.81. The company's market cap stands at $13.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock declined by 12.0% to $1.32. The company's market cap stands at $9.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock decreased by 11.91% to $1.85. The market value of their outstanding shares is at $37.4 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) shares decreased by 11.08% to $3.13. The market value of their outstanding shares is at $27.9 million. </li>
<li>Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) stock decreased by 10.5% to $18.0. The company's market cap stands at $4.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADVM

BJDX

BLUE

CAPR

Envoy Medical, Inc. - Class A Common Stock

COCH

CRVO

CYCN

MRKR

STVN

TARA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BioRestorative Therapies Has Announced That The European Patent Office Has Issued A Notice Of Allowance For A New Patent Application Covering Key Aspects Of The Company's Allogeneic, Off-The-Shelf ThermoStem Metabolic Disease Platform

BioRestorative Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) revealed on Wednesday new preliminary 26 to 52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing <a href="https://www.benzinga.com/pressreleases/24/11/g41934718/biorestorative-therapies-reports-positive-preliminary-phase-2-brtx-100-clinical-data" target="_blank" rel="noreferrer noopener">Phase 2 trial of BRTX-100</a>.
BRTX-100 is a novel cell-based therapeutic engineered to target body areas with little blood flow.
A Phase 2 study is evaluating the safety and efficacy of BRTX-100 in treating cLDD. Up to 99 eligible subjects will be enrolled.
The 10 safety run-in subjects reported no serious adverse events (SAEs).
There was also no dose (40X106 cells) limiting toxicity at 26 to 52 weeks.
The company reported blinded clinical data on the secondary efficacy endpoint of at least a 30% decrease in pain measured on the Visual Analog Scale (VAS) and at least a 30% increase in function based on the Oswestry Disability Index (ODI) at week 52.
The blinded preliminary efficacy endpoint data demonstrated:
<ul>
<li>At 26 weeks, 70% of subjects (n=10) and 100% of subjects (n=4) at 52 weeks reported a &gt;30% improvement in VAS versus baseline.</li>
<li>At 12 and 26 weeks, 70% of subjects (n=10) had a &gt;30% improvement in ODI versus baseline.</li>
<li>At 52 weeks, 100% of subjects (n=4) had a &gt;30% improvement in ODI versus baseline.</li>
<li>At 26 weeks, 70% of subjects (n=10) reported a &gt;30% decrease in pain (VAS)&nbsp;and&nbsp;a &gt;30% increase in function (ODI).</li>
</ul>
BRTX Price Action: BRTX stock is down 1.22% at $1.62 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/24/11/41942999/griffon-surges-ahead-strong-q4-earnings-beat-dividend-hike-buyback-more" target="_blank" rel="noreferrer noopener">Griffon Surges Ahead: Strong Q4 Earnings Beat, Dividend Hike, Buyback &amp; More</a></li>
</ul>
Photo: One Photo via Shutterstock

BioRestorative Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results. Additionally, the company reported preliminary Phase 2 BRTX-100 clinical data showing a material decrease in pain and increased function.

BioRestorative Therapies Reports Preliminary Phase 2 BRTX-100 Clinical Data Showing A Material Decrease In Pain And Increase In Function

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.43) by 69.77 percent. This is a 133.33 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $233.60 thousand which missed the analyst consensus estimate of $350.00 thousand by 33.26 percent. This is a 660.91 percent increase over sales of $30.70 thousand the same period last year.

Earnings

Earnings Beats

Earnings Misses

BioRestorative Therapies Q3 EPS $(0.13) Beats $(0.43) Estimate, Sales $233.60K Miss $350.00K Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Previously, BioRestorative was licensed by the NYSDOH to act as a tissue bank for the processing of mesenchymal stem cells derived from autologous donors only.

BioRestorative Secures Expanded Tissue License From New York State Department Of Health; Allows For Processing Of Allogeneic Donor Tissue Material, Including Stem Cells, For Medical Research

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARDX

ATHA

BFRI

CDXC

HALO

LUCY

OCEA

PALI

PDEX

TOVX

TRIB

12 Health Care Stocks Moving In Thursday's After-Market Session

BioRestorative Therapies Announces Israel Patent Office Has Issued A Notice Of Allowance For A New Patent Application Covering Several Fundamental Aspects Of The Company's Allogeneic, Off-The-Shelf ThermoStem Platform

BioRestorative Therapies Announced That Its Chief Scientist And Vice President Of Research And Development, Francisco Silva, Will Present At The Annual International Federation For Adipose Therapeutics And Science Conference

Roth MKM analyst Jonathan Aschoff maintains BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) with a Buy and raises the price target from $15 to $18.

Price Target

Analyst Ratings

Roth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18

BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.55) by 9.09 percent.

BioRestorative Therapies Q2 2024 GAAP EPS $(0.50) Beats $(0.55) Estimate

BioRestorative Therapies Announces Notice Of Allowance For Patent Related To Its ThermoStem Platform

WIIM

BioRestorative Therapies shares are trading higher after the company announced it regained compliance with the Nasdaq.

BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with <a href="https://www.benzinga.com/pressreleases/24/06/g39353187/biorestorative-therapies-regains-compliance-with-nasdaq-listing-rule-5250-c-1-reports-first-quarte">listing requirements.&nbsp;</a>
The Details:
BioRestorative Therapies reported a net loss for the first quarter of $2.2 million, or 33 cents per share, compared to a net loss of $7.2 million, or $1.93 per share, from the same period last year. The company reported a loss from operations of $4.1 million, a 29% improvement from the $5.8 million loss from operations for the comparable period of 2023. 
The company also reported it ended the first quarter with cash, cash equivalents, and investments held in marketable securities of $16.4 million.&nbsp;
BioRestorative Therapies shares are moving on heavy trading volume Monday following the announcement. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 3 million shares have been traded in the session, compared to the stock&#8217;s 100-day average of 2.014 million shares.
Related News: <a href="https://www.benzinga.com/news/24/06/39337862/whats-going-on-with-carnivals-stock">What&#8217;s Going On With Carnival&#8217;s Stock?</a>
<h2 class="wp-block-heading">How To Buy BRTX Stock: </h2>
By now you're likely curious about how to participate in the market for BioRestorative Therapies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of BioRestorative Therapies which is trading at $2.23 as of publishing time, $100 would buy you 44.84 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
BRTX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, BioRestorative Therapies shares are up 18.4% at $2.19 at the time of publication Monday.
Image: PublicDomainPictures from Pixabay

What's Going On With BioRestorative Therapies Stock?

BioRestorative Therapies Regains Compliance With Nasdaq Listing Rule

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 edging higher on Thursday.
The Dow traded down 0.21% to 38,629.82 while the NASDAQ rose 0.26% to 17,654.01. The S&amp;P 500 also rose, gaining, 0.13% to 5,428.07&nbsp; .
Check This Out: <a href="https://www.benzinga.com/news/24/06/39310076/alphabet-dropbox-and-2-other-stocks-insiders-are-selling">Alphabet, Dropbox And 2 Other Stocks Insiders Are Selling</a> 
Leading and Lagging Sectors Information technology shares jumped by 1.1% on Thursday.
In trading on Thursday, industrials shares fell by 0.9%.
Top Headline
Shares of Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) fell around 16% during Thursday&#8217;s session following mixed first-quarter earnings including an 8.9% drop in same store sales.
The company reported a first-quarter FY25 sales decline of 9.5% year-on-year to $1.510 billion, missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimates of 85 cents.
Signet expects second-quarter sales of $1.46 billion – $1.52 billion, versus the consensus of $1.508 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares shot up 33% to $1.77 after the company announced that it engaged in advanced discussions for a ThermoStem license with a regenerative medicine firm.</li>
<li>Shares of Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) got a boost, surging 275% to $2.68 after the company announced that it signed a memorandum of understanding and intends to appoint Bounce Electric 1 Private as its contract manufacturing partner for sales of the i300 in India.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares were also up, gaining 12% to $0.3351 after the company announced that it signed a $30 million purchase order from Nephron Pharmaceuticals for prefillable copolymer syringes.</li>
</ul>
Equities Trading DOWN
<ul>
<li>J.Jill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) shares dropped 18% to $32.35. J.Jill priced its public offering of 2 million common stock at $31 per share.</li>
<li>Shares of Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) were down 36% to $0.0933 after the company announced that it will be implementing a 1-for-40 reverse stock split.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) was down, falling 35% to $0.4443 after the company announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica. Also, Needham, Canaccord Genuity and HC Wainwright downgraded their respective ratings on the stock.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/06/39310159/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yie">Uber To Rally Around 38%? Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a> 
Commodities In commodity news, oil traded down 0.1% to $78.47 while gold traded down 1.6% at $2,317.20.
Silver traded down 4.1% to $29.025 on Thursday, while copper fell 1.8% to $4.4840.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.31%, Germany's DAX dipped 1.96% and France's CAC 40 tumbled 1.99%. Spain's IBEX 35 Index fell 1.59%, while London's FTSE 100 slipped 0.63%.
Industrial production in the Eurozone fell by 0.1% month-over-month in April following a revised 0.5% gain in the prior month. The annual inflation rate in Spain accelerated for the third month to 3.6% in May.
Germany&#8217;s wholesale prices declined by 0.7% year-over-year in May compared to a 1.8% fall in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei falling 0.40%, Hong Kong's Hang Seng Index gaining 0.97%, China's Shanghai Composite Index falling 0.28% and India's S&amp;P BSE Sensex gaining 0.27%.
The Hong Kong Monetary Authority kept its base rate unchanged at 5.75% during its latest meeting.
Economics
<ul>
<li>U.S. initial jobless claims rose by 13,000 to 242,000 in the week ending June 8, compared to market estimates of 225,000.</li>
<li>U.S. producer prices fell by 0.2% month-over-month in May versus market estimates of a 0.1% gain and following a 0.5% increase in April.</li>
<li>U.S. natural-gas supplies rose 74 billion cubic feet during the week ended June 7, versus market estimates of a 75 billion cubic feet gain.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39310078/top-3-tech-and-telecom-stocks-youll-regret-missing-in-q2">Top 3 Tech And Telecom Stocks You&#8217;ll Regret Missing In Q2</a>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

BURU

CARA

JILL

STSS

ZAPP

S&P 500 Edges Higher; J.Jill Shares Plunge

Shares of Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% <a href="https://www.benzinga.com/news/earnings/24/06/39311023/shining-through-challenges-signet-jewelers-reports-mixed-q1-results-optimistic-outlook">drop in same store sales</a>.
The company reported a first-quarter FY25 sales decline of 9.5% year-on-year to $1.510 billion, missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimates of 85 cents.
Signet expects second-quarter sales of $1.46 billion – $1.52 billion, versus the consensus of $1.508 billion.
Signet Jewelers shares dipped 12.5% to $94.81 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>BioRestorative Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares climbed 66.3% to $2.22 after the company announced that it engaged in advanced discussions for a ThermoStem license with a regenerative medicine firm.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) gained 59.3% to $1.14 after the company announced that it signed a memorandum of understanding and intends to appoint Bounce Electric 1 Private as its contract manufacturing partner for sales of the i300 in India..</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares climbed 39% to $0.4162 after the company announced that it signed a $30 million purchase order from Nephron Pharmaceuticals for prefillable copolymer syringes.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) jumped 35.1% to $0.8101.</li>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) gained 28% to $5.95</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) rose 24% to $2.8999.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) gained 23.6% to $0.8070.</li>
<li>Vivani Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) jumped 23% to $2.0050 after the company announced the FDA cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 22.8% to $1.84.</li>
<li>Barnes &amp; Noble Education, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) jumped 22.2% to $8.40. Barnes &amp; Noble Education named Jonathan Shar as new Chief Executive Officer.</li>
<li>John Wiley &amp; Sons, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) rose 19.3% to $42.62 as the company reported results for the fourth quarter and fiscal year ended April 30, 2024.</li>
<li>Longeveron Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares climbed 18.8% to $2.15. Longeveron shares jumped over 120% on Wednesday following the circulation of a Zacks Small Cap Research note valuing the stock at $15.10 per share.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) gained 17.3% to $16.10.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares rose 14.9% to $0.70 after surging 5% on Wednesday.</li>
<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) jumped 14.3% to $26.92. Roth MKM analyst Justin Clare maintained American Superconductor with a Buy and raised the price target from $20 to $27.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) gained 14.2% to $0.7450.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) rose gained 14.2% to $1,707.99 after the company posted stronger-than-expected results for its second quarter. The company declared a quarterly dividend of $5.25 per share and also announced a 10-for-1 forward stock split. Broadcom boosted its fiscal year 2024 revenue guidance to approximately $51 billion, up from approximately $50 billion.</li>
<li>Bitfarms Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) jumped 12.3% to $2.73. The company on Thursday issued new guidance for 2025 after announcing an agreement to develop power capacity in Pennsylvania.</li>
<li>United Homes Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) gained 12.3% to $7.34.</li>
<li>Grupo Supervielle S.A.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) gained 10.7% to $7.26 after rising 6% on Wednesday.</li>
<li>Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) rose 8.3% to $10.36.</li>
<li>Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) gained 7% to $67.87 following better-than-expected quarterly results.</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 6.7% to $189.30 after CEO Elon Musk said the company&#8217;s shareholder resolutions are passing with significant margins.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares fell 48.8% to $0.27.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) fell 37.1% to $0.4202 after the company announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica. Also, Needham, Canaccord Genuity and HC Wainwright downgraded their respective ratings on the stock.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) fell 36.1% to $0.0933 after the company announced that it will be implementing a 1-for-40 reverse stock split.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) shares declined 30.9% to $1.07. DayDayCook shares jumped 198% on Wednesday after the company announced it has acquired Omsom.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) fell 29% to $0.50. CERo Therapeutics completed IND-Enabling activities following successful manufacturing runs for lead compound CER-1236.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) declined 28% to $4.1350.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares fell 26.2% to $0.5712 after surging around 19% on Wednesday.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) fell 19% to $0.5899.</li>
<li>J.Jill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) fell 17.8% to $32.48. J.Jill priced its public offering of 2 million common stock at $31 per share.</li>
<li>Tellurian Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TELL#NYSE">TELL</a>) dipped 16.5% to $0.6328</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares fell 13.1% to $0.7401 after the company announced it will effect a reverse stock split.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares fell 11.7% to $0.5712 after gaining 10% on Wednesday.</li>
<li>Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) shares fell 11.4% to $44.60 after the company posted downbeat results for its first quarter on Wednesday.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) fell 10.8% to $14.13 after the company revised its 2024 group production guidance down due to the impact of weather events on the Salares Norte project.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) dipped 9.8% to $128.74. Repligen named Olivier Loeillot as Chief Executive Officer, effective Sept. 1.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) fell 6.3% to $10.41.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39311150/top-3-tech-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Tech Stocks That May Fall Off A Cliff This Month</a>

AMSC

AVGO

BITF

BMEA

BNED

CERO

Core Scientific, Inc. - Class A Common Stock

CORZ

IONM

KYTX

NWTN

PARA

PLAY

PRFX

PTPI

RGEN

SPCE

SUPV

TELL

TSLA

VANI

WHLR

WLYB

Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock rose 27.4% to $1.72. The market value of their outstanding shares is at $11.6 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares rose 26.84% to $0.66. The market value of their outstanding shares is at $3.3 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock moved upwards by 23.58% to $0.37. The company's market cap stands at $6.5 million. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) stock moved upwards by 20.95% to $5.6. The market value of their outstanding shares is at $201.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 20.66% to $0.41. The company's market cap stands at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock fell 47.6% to $0.27 during Thursday's regular session. The market value of their outstanding shares is at $2.4 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock decreased by 40.28% to $0.42. The company's market cap stands at $6.3 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) stock declined by 35.97% to $0.44. The company's market cap stands at $23.7 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) shares decreased by 15.63% to $1.08. The company's market cap stands at $64.9 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock fell 13.66% to $1.96. The company's market cap stands at $4.8 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares fell 12.61% to $0.47. The market value of their outstanding shares is at $3.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

ISPC

KRON

12 Health Care Stocks Moving In Thursday's Intraday Session

The latest update is out from BioRestorative Therapies ( ($BRTX) ). In an effort to streamline its stock offering processes, the Company has termin...

BioRestorative Therapies Ends Agreement with JonesTrading

BioRestorative Therapies ( ($BRTX) ) has shared an update. BioRestorative Therapies, Inc. is set to reveal promising data from its Phase 2 clinical...

BioRestorative Therapies to Announce Phase 2 Trial Data

BioRestorative Therapies (BRTX) announced new preliminary 26-52 week blinded data from the first 10 patients with chronic lumbar disc disease, cLDD...

BioRestorative Therapies reports Phase 2 BRTX-100 clinical data

BioRestorative Therapies GAAP EPS of -$0.13 beats by $0.30

Comments

BioRestorative Therapies

BioRestorative Therapies (BRTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga